American Heart Journal
Volume 142, Issue 2 , Pages 363-374 , August 2001

Highlights from the American College of Cardiology Forty-Ninth Annual Scientific Sessions: March 18 to 21, 2001

References 

  1. Shepherd J, Cobbe SM, Ford I, et al.  Prevention of the coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301–1307
  2. Shepherd J, Cobbe SM, Ford I, et al.  Prevention of the coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301–1307
  3. Long-Term Intervention with Pravastatin in Ischaemic Disease LIPID Study Group . Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad base of initial cholesterol levels. N Engl J Med. 1998;339:1349–1357
  4. Sacks F, Pfeffer M, Moye L, et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001–1009
  5. Lindahl B, Toss H, Siegbahn A, et al.  Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N Engl J Med. 2000;343:1139–1147
  6. Ridker PM, Cushman M, Stampfer MJ, et al.  Inflammation, aspirin, and risks of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973–979
  7. Ridker PM, Rifai N, Pfeffer MA, et al.  Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation. 1999;100:230–235
  8. Fragmin and Fast Revascularisation During Instability in Coronary Artery Disease FRISC II Investigators . Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet. 1999;354:708–715
  9. Cannon C. TACTICS-TIMI 18 (Treat Angina With Aggrastat and Determine Cost of Therapy With an Invasive or Conservative Strategy). Proceedings of the American Heart Association Scientific Sessions; 2000, New Orleans, La. New Orleans: The Association; 2000;
  10. Nishimura RA, Hayes DL, Holmes DR, et al.  Mechanism of hemodynamic improvement by dual chamber pacing for severe left ventricular dysfunction: an acute Doppler and catheterization hemodynamic study. J Am Coll Cardiol. 1995;25:281–288
  11. Auricchio A, Stellbrink C, Block C, et al.  Effect of pacing chamber and atrioventricular delay on acute systolic function of paced patients with congestive heart failure. Circulation. 1999;99:2993–3001
  12. Love MP, McMurray JJ. Endothelin in heart failure: a promising therapeutic target?. Heart. 1997;77:93–94
  13. Sutsch G, Kiowski W, Yan XW, et al.  Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation. 1998;98:2262–2268
  14. CAPRIE Steering Committee . A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329–1339
  15. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med. 1998;339:799–805
  16. Herzog CA, Ma JZ, Collins AJ. Long-term outcome of dialysis patients in the United States with coronary revascularization procedures. Kidney Int. 1999;56:324–332
  17. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41

☆ Reprint requests: Mark East, MD, Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715. E-mail: east0001@mc.duke.edu

☆☆ Am Heart J 2001;142:363-74.

PII: S0002-8703(01)62835-7

doi: 10.1067/mhj.2001.117061

American Heart Journal
Volume 142, Issue 2 , Pages 363-374 , August 2001

Article Tools